Populations at risk of infant mortality, infectious diseases, and other debilitating conditions require careful surveillance so policy makers, practitioners, and researchers can monitor progress and understand key factors underlining the conditions.
Abt Associates has developed surveillance systems for conditions across the lifespan—from birth defects and infant mortality, to ALS and Chronic Fatigue Syndrome. We also provide the accurate, thorough, timely data to create a clear picture of immunization levels among diverse populations. Our surveillance systems cover all ages, racial and ethnic groups, and the U.S. and developing countries.
Abt gathers data using both unobtrusive observation and direct measurement. We are equally adept at using single-mode methodologies and mixed-mode surveys. Our comprehensive expertise helps ensure that our surveys are accurate and complete.
Abt offers a team of professional health services researchers with knowledge and expertise in health economics, biostatistics, health management and policy, and program evaluation. We have extensive experience using quantitative data, including abstracting and using information from survey data.
Our capabilities include:
Developing risk adjustment models;
Designing health-related evaluation studies;
Using complex statistical methods to analyze data;
Developing interview guides, protocols, and conducting research interviews; and
Applying insights from health economics to influence health policy.
UNITED STATES: How do you track and prepare for a potential influenza epidemic when the virus is ever-changing?
The Centers for Disease Control and Prevention (CDC) have long relied on Abt Associates to monitor and provide vital research in the epidemiology of influenza, including estimating the effectiveness of influenza vaccines and antivirals. Having already built and implemented systems to evaluate vaccine effectiveness and monitor the virus in children, health care providers and pregnant women, Abt and its survey research arm, Abt SRBI, were chosen to establish the first research infrastructure for epidemiologic studies of the influenza illness and prevention and treatment strategies in advance of a pandemic. This new research platform will allow the CDC to quickly ascertain the presentation and severity of any new pandemic strain of influenza, as well as evaluate antiviral and vaccine effectiveness.
CLIENT: CDC / PROJECT: The Epidemiology of Novel Influenza Virus Infection and Evaluation of Antiviral and Vaccine Effectiveness